A study of bleximenib, venetoclax and azacitidine for treatment of participants with newly diagnosed acute myeloid leukemia (cAMeLot-2)
| ISRCTN | ISRCTN37340032 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN37340032 |
| ClinicalTrials.gov (NCT) | NCT06852222 |
| Clinical Trials Information System (CTIS) | Nil known |
| Integrated Research Application System (IRAS) | 1011871 |
| Protocol serial number | 75276617AML3001, CPMS 66634 |
| Sponsor | Janssen-Cilag International NV |
| Funder | Janssen Research and Development, LLC |
- Submission date
- 20/03/2025
- Registration date
- 19/08/2025
- Last edited
- 01/09/2025
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Acute myeloid leukemia (AML) is a highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow, and it affects blood cells that fight bacterial infections. Treatment options for AML are limited, survival rates are poor, and many patients are ineligible for standard chemotherapy treatments due to toxicity.
The study drug, bleximenib, specifically targets and blocks the interaction between the proteins histone-lysine N-methyltransferase 2A (KMT2A) and menin. In AML with KMT2A gene rearrangements (KMT2Ar) or NPM1 mutations (NPM1m), blocking this protein-protein interaction kills leukemia cells and helps stop the disease from worsening.
The purpose of this study is to find out how well bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA for the treatment of participants with KMT2Ar or NPM1m AML.
Who can participate?
Participants with newly diagnosed AML with KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy.
What does the study involve?
Study will be conducted in 3 phases:
1. Screening (Up to 28 days): Confirm if the participants can take part in the study.
2. Treatment Phase: Participants will be randomly (by chance) assigned in the following arms:
• Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA)
• Arm B Placebo and VEN + AZA
Participants will receive treatment until disease progression, unacceptable toxicity, or if any of the discontinuation criteria defined in the protocol are met.
3. Follow-up Phase: Participants will be followed-up for their overall health throughout the study until death, withdrawal of consent, loss to follow-up, or end of the study, whichever occurs first.
During the study, some tests such as blood & urine tests and physical examination will be performed. Information on side effects will be collected while participants are receiving study treatment and for a period of time after study treatment is discontinued. The overall duration of the study will be approximately 4.5 years.
What are the possible benefits and risks of participating?
There is no established benefit to participants of this study. Based on scientific theory adding bleximenib to VEN+AZA may improve acute myeloid leukaemia outcomes. However, this cannot be guaranteed because bleximenib is still under investigation as a treatment, and it is not known whether the study treatment will work.
If participants are assigned to the placebo treatment group, they will receive VEN+AZA along with placebo during this study.
Participants may experience some benefit from participation in the study that is not due to receiving study treatment but due to regular visits and assessments monitoring overall health. Participation may help other people with acute myeloid leukaemia in the future.
Participants may have side effects from the drugs or procedures used in this study that may be mild to severe and even life-threatening, and they can vary from person to person.
The potential risks for bleximenib are based on how the drug works, results from laboratory studies, people who have received bleximenib, or general risks for new medicines. These may include:
• Differentiation Syndrome (when there is a large, rapid release of immune substances known as cytokines from leukemia cells after treatment with anticancer drugs)
• Tumour Lysis Syndrome (when large numbers of leukaemia cells die in a short period of time)
• Cytopenias (reduction in blood cells)
• Infections
• Changes to heart rhythm
• Fertility effects
There may also be other potential risks associated with bleximenib.
The participant information sheet and informed consent form, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining the known risks to participating in the study. Not all possible side effects and risks related to bleximenib are known at this moment. During the study, the sponsor may learn new information about bleximenib. The study doctor will tell participants as soon as possible about any new information that might make them change their mind about being in the study, such as new risks. To minimise the risk associated with taking part in the study, participants are frequently reviewed for any side effects and other medical events. Participants are educated to report any such events to their study doctor who will provide appropriate medical care. Any serious side effects that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team. There are no costs to participants to be in the study. The sponsor will pay for the study treatment and tests that are part of the study. The participant will receive reasonable reimbursement for study-related costs (e.g., travel/parking costs).
Where is the study run from?
Janssen-Cilag International NV (Netherlands)
When is the study starting and how long is it expected to run for?
March 2025 to August 2029
Who is funding the study?
Janssen Research and Development, LLC (Netherlands)
Who is the main contact?
JanssenUKRegistryQueries@its.jnj.com
Contact information
Public
50-100 Holmers Farm Way
High Wycombe
HP12 4DP
United Kingdom
| JanssenUKRegistryQueries@its.jnj.com |
Principal investigator
Derriford Road
Plymouth
PL6 8DH
United Kingdom
Scientific
50-100 Holmers Farm Way
High Wycombe
HP12 4DP
United Kingdom
| Phone | +44 800 731 8450 / +44 1494567 444 |
|---|---|
| medinfo@its.jnj.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Interventional double blind randomized parallel group placebo controlled trial |
| Secondary study design | Randomised parallel trial |
| Scientific title | A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy |
| Study acronym | cAMeLot-2 |
| Study objectives | Primary objective: To compare the efficacy of bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) as compared to placebo and VEN+AZA treatment. Secondary objectives: 1. To compare additional measures of the efficacy of bleximenib and VEN+AZA compared to placebo and VEN+AZA. 2. To assess the safety profile. 3. To assess symptoms, functioning, and health-related quality of life. 4. To characterize bleximenib drug levels in the blood. |
| Ethics approval(s) |
Approved 14/05/2025, London - Brighton & Sussex Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8140; brightonandsussex.rec@hra.nhs.uk), ref: 25/LO/0274 |
| Health condition(s) or problem(s) studied | Acute myeloid leukemia |
| Intervention | Experimental: Arm A: Bleximenib (administered orally) and Venetoclax (administered orally) + Azacitidine (administered intravenously or subcutaneously). Participants with acute myeloid leukemia (AML) will receive bleximenib in combination with venetoclax (VEN) and azacitidine (AZA) for 28-days treatment cycle and treatment will continue until progression or unacceptable toxicity. Placebo Comparator: Arm B: Placebo (administered orally) and Venetoclax (administered orally) + Azacitidine (administered intravenously or subcutaneously). Participants with AML will receive placebo in combination with VEN and AZA for 28-days treatment cycle, and treatment will continue until progression or unacceptable toxicity. |
| Intervention type | Drug |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | JNJ-75276617 [bleximenib] |
| Primary outcome measure(s) |
1. Percentage of Participants who Achieve Complete Remission (CR) |
| Key secondary outcome measure(s) |
1. Event-free survival (EFS). EFS is defined as the time from randomization to treatment failure, relapse, or death due to any cause, whichever occurs first. [Time Frame: Up to 4 years and 1 month] |
| Completion date | 27/08/2029 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 600 |
| Key inclusion criteria | 1. Be 18 years of age or older at the time of informed consent. 2. Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (≥) 10% bone marrow blasts per 2022 international Consensus Classification criteria. 3. Ineligible for intensive chemotherapy based on the criteria defined in the protocol. 4. Participants must have adequate hepatic and renal function. 5. A female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment. 6. A male participant must agree to use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment. 7. Must sign an informed consent form indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. |
| Key exclusion criteria | 1. Diagnosis of acute promyelocytic leukemia (APL). 2. Known active leukemic involvement of the central nervous system (CNS). 3. Recipient of solid organ transplant. 4. Any cardiac disorders such as: 4.1. Heart attack. 4.2. Uncontrolled/unstable chest pain. 4.3. Congestive heart failure. 4.4. Uncontrolled or symptomatic irregular heartbeat. 4.5. Blockage of a blood vessel to the brain. 4.6. Transient ischemic (decreased oxygen in tissue) attack within 6 months of randomization. 5. Active infectious hepatitis. 6. Live, attenuated vaccine within 4 weeks of randomization. 7. Known allergies, hypersensitivity, or intolerance of bleximenib excipients. |
| Date of first enrolment | 14/04/2025 |
| Date of final enrolment | 19/09/2027 |
Locations
Countries of recruitment
- United Kingdom
- England
- Scotland
- Australia
- Austria
- Belgium
- Brazil
- Canada
- China
- Denmark
- France
- Germany
- Greece
- Hungary
- Israel
- Italy
- Japan
- Mexico
- Poland
- Portugal
- Spain
- Taiwan
Study participating centres
Edinburgh
Lothian
EH4 2XU
United Kingdom
Hills Road
Cambridge
CB2 0QQ
United Kingdom
Derriford
Plymouth
PL6 8DH
United Kingdom
Canterbury
CT1 3NG
United Kingdom
Brighton
BN2 5BE
United Kingdom
Charter Way
Turner Road
Colchester
CO4 5JL
United Kingdom
Liverpool
L7 8YA
United Kingdom
Great Maze Pond
London
SE1 9RT
United Kingdom
Worthing
BN11 2DH
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | Not provided at time of registration |
Editorial Notes
01/09/2025: Internal review.
20/03/2025: Trial's existence confirmed by NHS HRA.
